Screener / SEC EDGAR /CIK 0001832466 /10-K filed Feb 27, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Financials · Health Insurance

Alignment Healthcare, Inc. ALHC

Compare with peers Embed
Planned sales, announced before they happen

6 trading plans running, 49 Form 144 notices for $317.9M

10-Q, 10-K and Form 144
Plans running now 6 John Kao, Dawn Maroney, Hyong (Ken) Kim, M.D., Sebastian Burzacchi, Joseph Konowiecki, Andreas Wagner
Plans adopted 22 reported since May 4, 2023 Form 144 notices 49 $317.9M the sellers expected to sell

What ALHC's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.

Plans adopted or ended

Trading plans · XBRL, 10-Q and 10-K

From Mar 12, 2025 to Jun 30, 2027. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired. The ten newest plans are drawn; all are in the table.

InsiderWhatDateReported in
John Kao
Chairman and Chief Executive Officer(2)
Adopted 10b5-1 plan May 27, 2026 10-Q Jul 30, 2026
Dawn Maroney
President
Adopted 10b5-1 plan Mar 13, 2026 10-Q Apr 30, 2026
Hyong (Ken) Kim, M.D.
Chief Medical Officer
Adopted 10b5-1 plan Mar 13, 2026 10-Q Apr 30, 2026
Sebastian Burzacchi
Chief Operating Officer - MSO
Adopted 10b5-1 plan Mar 13, 2026 10-Q Apr 30, 2026
Joseph Konowiecki
Chairman of the Board
Adopted 10b5-1 plan Mar 4, 2026 10-Q Apr 30, 2026
Andreas Wagner
Chief Human Resources Officer
Adopted 10b5-1 plan Nov 21, 2025 10-K Feb 27, 2026
John Kao
Chief Executive Officer
Adopted 10b5-1 plan Nov 21, 2025 10-K Feb 27, 2026
Christopher Joyce
Chief Legal & Administrative Officer
Adopted 10b5-1 plan Sep 8, 2025 10-Q Oct 30, 2025
What the company wrote
During the fiscal quarter ended September 30, 2025, our executive officers and directors adopted or terminated, as applicable, the following trading arrangements that are intended to satisfy the affirmative defense of Rule 10b5-1(c): Name & Title Date of Adoption Date of Termination Duration of Trading Arrangement Maximum Number of Securities to be Sold (1) Christopher Joyce, Chief Legal & Administrative Officer 9/8/2025 N/A 12/8/2025 – 9/11/2026 95,455 (1) Securities reported in this column include securities subject to limit orders and such orders may not fill if limit order conditions are not met. The actual number of shares sold under the plan will depend on the vesting of certain performance-based equity awards and the number of shares withheld or sold satisfy our income tax withholding obligations and may vary from the number provided herein. The number of performance share units included in plans assumes awards are earned at target.
Dawn Maroney
President
Adopted 10b5-1 plan May 22, 2025 10-Q Jul 30, 2025
What the company wrote
During the fiscal quarter ended June 30, 2025, our executive officers and directors adopted or terminated, as applicable, the following trading arrangements that are intended to satisfy the affirmative defense of Rule 10b5-1(c): Name & Title Date of Adoption Date of Termination Duration of Trading Arrangement Maximum Number of Securities to be Sold (1) Dawn Maroney, President 5/22/2025 N/A 8/25/2025 – 6/30/2026 410,000 (1) Securities reported in this column include securities subject to limit orders and such orders may not fill if limit order conditions are not met. The actual number of shares sold under the plan will depend on the vesting of certain performance-based equity awards and the number of shares withheld or sold satisfy our income tax withholding obligations and may vary from the number provided herein. The number of performance share units included in plans assumes awards are earned at target.
Thomas Freeman
Chief Financial Officer
Ended 10b5-1 plan Mar 14, 2025 10-Q May 1, 2025
John Kao
Chief Executive Officer
Adopted 10b5-1 plan Mar 12, 2025 10-Q May 1, 2025
Andreas Wagner
Chief Human Resources Officer
Adopted 10b5-1 plan Mar 11, 2025 10-Q May 1, 2025
Christopher Joyce
Chief Legal & Administrative Officer
Adopted 10b5-1 plan Nov 27, 2024 10-K Feb 27, 2025
Dawn Maroney
President
Adopted 10b5-1 plan Nov 25, 2024 10-K Feb 27, 2025
Thomas Freeman
Chief Financial Officer
Ended 10b5-1 plan Nov 20, 2024 10-K Feb 27, 2025
Hyong (Ken) Kim, M.D.
Chief Medical Officer
Adopted 10b5-1 plan Sep 5, 2024 10-Q Oct 29, 2024
What the company wrote
During the fiscal quarter ended September 30, 2024, our executive officers and directors adopted the following trading arrangements that are intended to satisfy the affirmative defense of Rule 10b5-1(c): Name & Title Date of Adoption Duration of Trading Arrangement Maximum Number of Securities to be Sold (1) Hyong (Ken) Kim, M.D. Chief Medical Officer 09/05/2024 12/5/2024 - 8/8/2025 145,034 (1) Securities reported in this column include securities subject to limit orders and such orders may not fill if limit order conditions are not met.
Christopher Joyce
Chief Legal & Administrative Officer
Adopted 10b5-1 plan Mar 15, 2024 10-Q May 2, 2024
Jeffrey Margolis
Director
Adopted 10b5-1 plan Mar 15, 2024 10-Q May 2, 2024
Thomas Freeman
Chief Financial Officer
Adopted 10b5-1 plan Mar 15, 2024 10-Q May 2, 2024
Hakan Kardes
Chief Experience Officer
Adopted 10b5-1 plan Mar 14, 2024 10-Q May 2, 2024
Hyong (Ken) Kim, M.D.
Chief Medical Officer
Adopted 10b5-1 plan Mar 14, 2024 10-Q May 1, 2025
John Kao
Chief Executive Officer
Adopted 10b5-1 plan Mar 14, 2024 10-Q May 2, 2024
Robert Scavo
Chief Information Officer
Adopted 10b5-1 plan Mar 14, 2024 10-Q May 1, 2025
Dawn Maroney
President, Markets
Adopted 10b5-1 plan Mar 13, 2024 10-Q May 2, 2024
Show the other 16 plans

From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since May 4, 2023.

Notices of planned sales

Form 144 · Form 144 XML, SEC

What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).

FiledSellerSharesValue
Nov 9, 2026 Joseph Konowiecki
Chairman / EVP, Corporate Affairs
5,500 $40K
Oct 5, 2026 Hyong (Ken) Kim, M.D.
Chief Medical Officer
36,000 $305K
Sep 16, 2026 Joseph Konowiecki
Director / EVP, Corporate Affairs
26,000 $226K
Sep 10, 2026 JEK TRUST U/A DTD 02/08/2021
Director, Officer
500,000 $6.5M
Sep 9, 2026 Dawn C. Maroney
President
130,000 $1.7M
Sep 9, 2026 John Kao
Chief Executive Officer / Director
405,000 $5.3M
Aug 14, 2026 DAWN MARONEY
Officer
5,000 $67K
Jul 15, 2026 DAWN MARONEY
Officer
177,068 $3.8M
Jul 10, 2026 JEK TRUST U/A DTD 02/08/2021
Director, Officer
596,000 $12.5M
Jul 1, 2026 Joseph Konowiecki
Director
25,000 $600K
Jun 26, 2026 Joseph Konowiecki
Director
25,000 $575K
Jun 18, 2026 Joseph Konowiecki
Director
25,000 $550K
Jun 12, 2026 HYONG J KIM
Officer
35,951 $728K
Jun 12, 2026 SEBASTIAN BURZACCHI
Officer
1,142 $23K
Jun 11, 2026 Joseph Konowiecki
Director
25,000 $525K
May 11, 2026 JEK TRUST U/A DTD 02/08/2021
Director, Officer
596,000 $10.7M
Apr 15, 2026 DAWN MARONEY
Officer
90,000 $1.9M
Apr 7, 2026 JEK TRUST U/A DTD 02/08/2021
Director, Officer
548,000 $10.2M
Apr 6, 2026 James M. Head
Chief Financial Officer
12,000 $224K
Apr 1, 2026 Christopher Joyce
Officer
18,013 $317K
Mar 23, 2026 JEK TRUST U/A DTD 02/08/2021
Director, Officer
118,000 $2.0M
Mar 19, 2026 ANDREAS WAGNER
Officer
11,602 $211K
Mar 16, 2026 Hyong (Ken) Kim, M.D.
Chief Medical Officer
38,762 $659K
Mar 16, 2026 Sebastian Burzacchi
Chief Operating Officer - MSO
16,987 $289K
Mar 16, 2026 Christopher Joyce
Chief Legal & Administrative Officer
27,592 $469K
Mar 16, 2026 Dawn C. Maroney
President
40,643 $691K
Mar 16, 2026 John Kao
Chief Executive Officer
80,788 $1.4M
Mar 16, 2026 Andreas P. Wagner
Chief Human Resources Officer
13,271 $225K
Mar 16, 2026 Robert L. Scavo
Chief Information Officer
12,145 $206K
Mar 10, 2026 JEK TRUST U/A DTD 02/08/2021
Director, Officer
180,000 $3.3M
Mar 10, 2026 Robert L. Scavo
Chief Information Officer
4,100 $76K
Mar 10, 2026 Dawn Maroney
President
30,000 $553K
Mar 10, 2026 John Kao
Chief Executive Officer
50,000 $922K
Mar 4, 2026 ANDREAS WAGNER
Officer
21,118 $390K
Feb 9, 2026 Andreas Wagner
Chief Human Resources Officer
22,500 $489K
Jan 6, 2026 DAWN MARONEY
Officer
318,152 $6.7M
Jan 6, 2026 HYONG J KIM
Officer
16,506 $347K
Dec 23, 2025 Robert Scavo
Chief Information Officer
68,000 $1.4M
Dec 23, 2025 Christopher Joyce
Chief Legal & Admin. Officer
15,000 $303K
Dec 23, 2025 Dawn Maroney
President
275,000 $5.6M
Dec 23, 2025 John Kao
Chief Executive Officer
600,000 $12.1M
Dec 23, 2025 Hyong (Ken) Kim, M.D.
Chief Medical Officer
13,000 $262K
Dec 15, 2025 DAWN MARONEY
Officer
213,319 $4.1M
Dec 12, 2025 DAWN MARONEY
Officer
16,681 $324K
Dec 11, 2025 Sebastian Burzacchi
Chief Operating Officer - MSO
12,585 $242K
Dec 10, 2025 JEK TRUST U/A DTD 02/08/2021
Director, Officer
540,000 $10.4M
Dec 10, 2025 General Atlantic (ALN HLTH), L.P.
Affiliate
11,119,494 $206.5M
Dec 8, 2025 CHRISTOPHER J. JOYCE
Officer
30,317 $593K
Nov 25, 2025 Joseph Konowiecki
Director
25,000 $475K
Show the other 41 notices

From the Form 144 XML filed with the SEC, since Nov 25, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.

Sources

Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.

Also

Insider trades: the Form 4s for the sales these plans led to.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ALHC/export.csv") into a cell.

Next:Owners
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.